:: Przegląd tematu - Liver disease in patients with protein C and de-γ

nrzxfquxq

,belstaff outlet
Liver disease in patients with protein C and de-γ carboxy prothrombin levels in

Patients with cirrhosis PC: C and PC: Ag levels were significantly lower (PC: C: p 0.05). DCPC liver cancer patients were significantly higher (p <0.05). The average of the total PC: Ag 50%. However, the level of acute viral hepatitis DCPC compared with the control group no significant difference. Total prothrombin levels lower in patients with liver cirrhosis. * 23 * but higher in HCC patients, and its unabsorbed prothrombin levels were significantly higher than other groups. CONCLUSION: PC: C and PC: Ag in the liver disease is low (acute viral hepatitis PC: C excluded). Patients with liver cirrhosis and lower total prothrombin. Not absorb elevated levels of prothrombin may be used as screening for signs of primary liver cancer. DCPC can be used as a supplementary sign of primary liver cancer diagnosis. (Compiled Li Tong had) long-term treatment of antiviral nucleoside significance and limitations of chronic hepatitis B (on) JulesL. Dienstag (Published in: Hepatology: 42 (2005): 173 ~ 179) with lamivudine in clinical trials started in the early 90s, is the first approved oral treatment for chronic hepatitis B nucleoside similar objects, and in fact in these patients has been done for five consecutive years or longer treatment. Early use of lamivudine in patients with l-bed experience, the majority of patients failed to produce interferon response, and no other treatment options, early use of lamivudine people see hope. Treatment with this new drug has a very well tolerated, and compared with the placebo patients, the treatment was no difference in adverse reactions, after one year of treatment, histology, virology, serology and biochemical improvement . In addition, unlike interferon, lamivudine for patients with high levels of HBVDNA, patients with decompensated liver cirrhosis and chronic hepatitis B-related liver disease and the end of the patients underwent liver transplantation is effective. Recently, lamivudine has been shown to slow down the clinical progress, and prompt in patients with advanced liver fibrosis (6o% of them are cirrhosis of the liver) can prevent the occurrence of hepatocellular carcinoma. In short, it is. Rule interferon antiviral therapy, lamivudine is being developed, initial treatment focused on reducing high copy, the wild type, Hneng positive chronic hepatitis B patients. lamivudine therapy in this group of people More than half of the people histological necroinflammatory activity improved, fibrosis slowed, and in 3 consecutive years, a small number of patients treated, three-quarters of patients with liver cirrhosis reversed. However, in the past two decades, the prevalence is on the rise, researchers have recognized BeAg negative chronic hepatitis B global importance. discovered in Europe, most cases of chronic hepatitis B negative chronic hepatitis B showed BeAg, and North America and Asia the proportion of the population is rising. a disturbance of protein gene transcription and translation of the former BeAg core or core promoter HBV mutations in these patients, the number has HBVDNA levels lower than those observed BeAg positive chronic hepatitis B patients. However, The sub-group of patients may be at a serious histological but also to the development of chronic hepatitis. distinction between positive and HBeAg negative chronic hepatitis B patients HBeng in the anti-viral treatment,} Lu eAg rmeng seroconversion-positive patients the opportunity exists, which species may be sustained seroconversion and the treatment can be allowed to suspend a milestone in serum. In I-meng negative chronic hepatitis B patients,} jingling BeAg seroconversion is not an option or a treatment either goal, Although two-thirds of l-meng-negative patients treated with lamivudine for one year, I-IBVDNA, and histologic activity was reduced, but a year later led to the majority of patients discontinuing treatment virological and biochemical recurrence. Thus, for all} Ding 3eI negative chronic hepatitis B patients, one year is not enough to nucleoside analogues, it is necessary to maintain long-term clinical effects of treatment. Of course, the researchers did not complete its pull- Mif order to discuss the effects of a treatment or no trade-offs to consider its downward trend, that is resistant to 24 *